Drug intelligence / Profile preview

ESN601

Development stage: Preclinical
Lead developer: Euroscreen
Modality: Small Molecules

Overview

**ESN601** is a small molecule GPCR modulator developed by Euroscreen Srl (now part of Ogeda SA, acquired by Astellas). It acts as a modulator of G-protein coupled receptors (GPCRs), a large family of membrane proteins involved in diverse physiological processes. The drug is in early discovery stage, primarily targeted for the treatment of autoimmune diseases, with its global R&D status listed as pending.[1][3][5][11][13]

Other names: ESN-601ESN601ESN 601

Beyond the preview

Go deeper on ESN601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESN601.

Explore the full profile